Merck KGaA signs up for Evinova's full AI clinical trial suite

Merck KGaA will adopt Evinova's full AI-powered suite for planning and managing clinical trials. This move by the German pharma giant follows similar agreements by Bristol Myers Squibb and Astellas, indicating a trend towards using integrated AI platforms from AstraZeneca's healthtech spin-out to optimise trial design and costs.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.